An open-label, 3-parallel panel, 3-period, pharmacokinetic interactions and tolerability study between elbasvir MK-8742 and ritonavir-boosted HIV protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers

Trial Profile

An open-label, 3-parallel panel, 3-period, pharmacokinetic interactions and tolerability study between elbasvir MK-8742 and ritonavir-boosted HIV protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2015

At a glance

  • Drugs Elbasvir (Primary) ; Atazanavir; Darunavir; Lopinavir; Ritonavir
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 19 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top